Q3 2020 Heska Corp Earnings Call
[laughter] and welcome to the Corporation third quarter 2020 earnings call. Today's conference is being recorded at this.
This time I would like to turn the conference over to Mr. job eager to director of Investor Relations. Please go ahead Sir.
Thank you and good morning, everyone welcome to Heska Corporation's earnings call for the third quarter EPS 20, Twond I didn't Johnny Guard head of Investor Relations for Heska.
Prior to discussing Heska is equal to 2020 results I would like to remind you that during the course of this call. We may make certain forward looking statements regarding future events or future financial performance with a capacity.
Need to caution you that any such forward looking statements are based on our current beliefs and expectations and involve known and unknown risks and uncertainties, which may cause actual results and performance to be materially different kinetic scrap standpoint that those forward looking statements factors.
Factors that could contribute.
If such differences are detailed in writing in this morning's earnings release outskirts Corporation, that's good Corporation's annual and quarterly guidance.
And elsewhere any forward looking statements speak only as of the time. They are made and Heska does not intend and specifically disclaim any obligation or intention to update any forward looking statements to reflect events that occur after the time such statements.
Yeah, but that's what's morning, Kevin Wilson, Heskas, Chief Executive Officer, and President and Catherine Grassman, Heskas, Chief Financial Officer, Mr. Wilson, and that's Grassman will provide details surrounding the results and then we will open the call to questions before.
Before I turn the call over to Kevin I would like to remind everyone that pets goods virtual industry. They burn 18 2020.
That's good management will present, the company's growth strategy at that special then including key new product demonstrations and they show a new geography integration that big a multiyear performance targets through registered for this event. Please visit the Investor Relations page.
I'm, sorry, you're excited and we hope to see you there.
With that being said it is now my pleasure to turn the call over to Kevin Wilson, That's good young President Kevin.
Hey, Thanks, John and good morning to everybody I know everybody's busy it's crazy news cycle, So I'm just going to jump.
Yep.
Today's call. We're pleased to report an exceptional third quarter all that exceeded expectations.
Outlined in this morning's release Heska teams delivered record level.
And near Universal strength across all key metrics.
Strong growth of 15.2% you know north American people, she loved consumables, bringing lot year to date performance to 9.7% yeah.
Yeah again captured solid international some performance exceptional results from our Spanish Australian in Germany games in particular.
Oh, that's good teams off because you did at a very high level to deliver results and once it's hard to find a bad metric.
In spite of macro uncertainty and strong competition, our strong performance across key metrics. We just don't believe that we will perform at the top end of the range is for most if not all.
What are your targets we've shared publicly.
Katherine will cover the specifics of the quarter in greater detail I do want to take a few moments to highlight a few things which may be helpful to investors all starting with our people.
Ask a seamless healthy and productive always continue to operate effectively Tom make flexible posture in each country much walk right.
I'm proud of our people and our investors should sleep well knowing that our performance is underpinned by many hundreds of dedicated heska employees. They work extremely hard to quickly solve challenges <unk> positive and sustainable way.
Most of any micro environmental challenges.
That's good stuff good people livengood lives doing great work, well the wonderful attitude and I'm honored to be part of this team and customers investors could be called a bar Association <unk>.
Similarly, the <unk> health care market broadly is doing great.
Industry continues to reaffirm its decades long resiliency.
It does it's in veterinary transgender wave outpaced most forecasts the companion animal population is growing at all time high rates increasing demand across an industry. That's been probably benefited by recent trends, which are more likely than not.
And enduring tailwind to long established underlying trends.
We are seeing an acceleration of long term trends in pet ownership.
Net favorable housing.
Positive pet ownership demographics increased human at home time, and pet households on an even stronger human part Bob Pet adoptions are up breeders are managing way didn't last.
First time those to veterinarians are.
And end user demand remains very strong.
Specific to ask this focus on point of care diagnostics.
Trends are similarly encouraging.
Curbside drop off and same day discharge procedures now firmly in place across most hospitals, we are seeing increased utilization and point of care testing.
Some of the increases from brand new testing.
Some smaller portion of the increase is at the point of care is testing that has migrated from central reference laboratories. Some of the Q3 utilization performance at how scalable is from Q to catch up.
Testing from pent up demand I'm sure deferred wellness lives, it's elective procedures and supply chain dampening that resulted from cold in 19 of talks earlier this year.
And some of our strong increase in subscriber utilization growth is being driven by Heska, new tariffs and new analyzers that are now making their way into the installed base.
Regardless of the weighting of each factor and there are others. The net result is that.
The underlying demand for point of care diagnostics tests, the barbarians sales very strong in the third quarter and the supporting trends continued to be strong and we believe sustainable.
Diagnostics at the point of care remains central and critical to growing veterinary services from the veterinarians perspective consumer goods sales <unk> sales and boarding revenues continued to decline while being more than offset by increased diagnostics surgeries price and other professional services that required licensure.
It turns out that there are more pets than ever that families are more focused on their pets people at home with their pets more regularly see pet health symptoms and households, now have increased schedule flexibility to take their pets to the veterinarian.
Veterinarians are very busy and sales have stuff.
Veterinarians are so busy in fact that they present they are less able to take time to make major decisions for technology and their practices in North America in particular companies such as has got continued to experience delays in clinic access by sales in that situation change, which has reduced opportunities for competitive blood instrumentation take away.
As a new imaging solutions installations.
This dynamic has also increased retention by the incumbent rather be in college have Scott one other company.
While we see this trend moderating over time it is likely to continue at some level over the next several quarters.
However in markets outside of North America.
It's much more first generation stage adoption, we anticipate increase in accelerating demand to adopt new point of care diagnostics for the first time.
And to capture first major upgrade cycles for early adopter, specifically in core Europe and Australia.
International Veterinarians are now more likely to adopt point of care diagnostics enthusiastic we for the first or second time.
For exactly the same reasons as North American veterinarians are increasing their utilization percentage of profitability from point of care testing.
The international rates are better and I've talked about certainly in full swing.
One is likely to largely unfold quickly over the next five to 10 years as a top three competitor and most of the markets. We are targeting it is a race. It has got tends to compete.
And to win.
And finally to conclude my remarks I'd.
I'd like to remind you of how were preparing for the future in Q3 research and development initiatives progressed in line with our timelines or commercial launch plans further solidified across several key projects also in line with my goals.
Integration with our recent international acquisitions progressed as expected.
And we are confident we can meaningfully grow and improve the profitability of these businesses over time for these reasons and more we remain confident in resolute our ability to deliver on the three core tenants of our 2018 through 23 strategic plan.
The double the geography and customer service, which we have done.
To double the products and revenue lines, which we offer which we were very very close to accomplishing.
And to continue to grow our core business, which we have done and anticipate continuing to do.
By adding and multiplying in and amongst these three major accomplishments, we anticipate a great performance in the back half of our five year plan.
With that I'll turn the call over to Catherine to detail the quarter's performance.
Thanks, Kevin and good morning, everyone.
As Kevin mentioned, we are pleased to report a strong performance for the third quarter 2020 consolidated revenue grew 81.3%, while largely benefited by our recent acquisitions at scale in TV and solid performance. During these uncertain times and our legacy casket business also contributed to growth on a year over year basis.
We report our results geographically in two segments, North America and international.
Our North America segment include Canada, and Mexico, well, our international segment consists of all countries outside of North America, and it comprised primarily Europe as of today.
North America segment revenue grew 16.4% contributing to this growth.
<unk> contributor that's what's growth of 15.2% and the level of Bell and growth in PVD would be expected return to sales of try hard a contract manufactured products, imbark, which experienced reduced customer demand and the comparative period and throughout 21 team.
The International segment performed at the high end of our expectations with strong consumable sales and capital equipment placements.
Consolidated gross margin declined approximately 240 basis points to 41.3% as anticipated negatively impacting consolidated gross margin on a comparative basis is the consolidation of scale a lower margin profile business. We continue to see bridging its margin gap of a meaningful synergy opportunity for heska.
Or intention to update guidance quarterly nor will we provide quarterly guidance moving forward, we will provide updates to our annual guidance based on events, we'd be insignificant to the understanding of our of our performance relevant to the expectations reset for her.
However, given the uncertainty of macro environmental factors, mostly related to the COVID-19 pandemic. We believe it is important to communicate with our investors and analysts on the health of our business, which is strong.
Such and it's Kevin indicated we are reaffirming our previously provided 2020 full year revenue and adjusted EBITDA guidance. We believe we have opportunity to achieve performance near the top end of all ranges previously disclosed on.
On last quarter's earnings call, we communicated a full your effective tax rate benefit of 12% to 15% based on changes in our underlying tax and business strategies. We are we're sending her guidance at this time and.
And some we're pleased with our financial performance in the third quarter and I look forward to sharing our multiyear financial targets and other T considerations that are upcoming investor day with that we'd like to open the call for your questions operator.
Thank you, ladies and gentlemen, if you'd like to ask a question can you speak about my preference spare one on your telephone keypad. Please I'm sure that the mute function on your telephone is switched off to allow your signal to reach our equipment again. Please press fire one ask a question.
The first question today comes from David Westenburg of Guggenheim Securities.
Alright, Thanks for taking my question and congrats on a on a good quarter uhm. So uhm it lab instruments outperformed us and you know I I think the commentary in the space is really and you kind of set in your prepared remarks or something like half of practices are really not allowing sales force back in and you know, it's probably not at a time that people and.
Style, new instruments can you clarify whether that is actually you got that on instruments or is that a lot on on the other and then in the same kind of token is this dynamic of all these practices not being open is that impacting subscription renewal or sought from subscription enrolled just you.
And the fact that you know your sales force that makes it seem touches but I you know there isn't capital purchase necessarily.
Just a little bit more commitment.
Yeah, So I'll I'll I'll talk about it.
Qualitatively and then Catherine Uhm, and then you want to add it hasn't stopped so the ability to get into clinics as.
<unk> the ability to heavier people travel was also not on a full stop and we've altered how.
How we approached customers as well so so it's more difficult in terms of installation of equipment.
But the but the instruments line hasn't hasn't entirely stopped by any stretch we leverage remote specialty.
A little bit more we've found ways to to get the customers and have a conversation so.
I think that's really the answer is is it hasn't stopped it's it's really hard to put out a pinpoint on it.
In terms of especially quarter to quarter their ability of how many are going to be installed in terms of finding subscription renewals that hasn't been a problem.
Customers tend to to transact I think I'm more easily with the incumbent they already have a positive relationship with them and extending that relationship for for additional benefits has not been a problem.
And so I think we've gotten a little bit of a bump from that dynamic in terms of when we extend the customer we have the opportunity maybe to offer an additional analyzer.
Or two and sometimes that's that's also positive just in terms of the instrumentation portion of that contract and she put new equipment and on top of what's already in and being renewed so Katherine I'm Gonna go ahead and add.
Nope I think that's that covers it.
Okay. Thank you and then in terms of Greenfield accounts outside the United States. You highlight done is is a growth strategy can you help us conceptualize what those accounts do right. Now is it you know no analyzer handhold on and lies or just kind of an old generation Greenfield kind of has a lot of.
Different in here.
Different accessibility and now I I get that that's a a better market for you and probably a faster growing one but I just didn't help us conceptualize what they look like right now so we kind of have a sense on on really you know.
You as a as a as a new player knows I guess skills not that new but penetrating those those markets.
Yeah I'd actually are you in your in your head on it we we are well.
Well entrenched in and that Margaret still has been servicing those customers S. I C B M in Spain.
And our efforts in France. So we have good longterm relationships with them I I I think you can divided into a couple of buckets you can divide again to folks who gets do less testing.
They do a more targeted approach to testing they do watch wellness testing, it's just an ingrained to the point, where they feel like they have to have a fall asleep.
So you you will you'll see people with nothing they'll use a reference lab.
They will use the local university.
Those types of things and then you see some folks who have a very incomplete portfolio. So they they might test for one or two parameters with an older machine maybe it uses a strip that's more of a target approach, but they're not running full panels and then not running them quickly. So it's not really integrated into their practice.
And then you will have a fair amount nah you know again, it's it's yes I have.
Or more who have something but they tend to be older generation, we see a lot more three part blood counts and.
In Europe, I think that the North American market is largely five part and has been for many years. So.
I would divided into those three buckets and then there's variability amongst countries you know you've been a better adoption in Germany. Let's say then you my opinion fiddly. So it's it's very difficult to to say Europe Broadway is it is very much a country by country cultural.
Uhm question as well.
Got it and then just maybe went on margin I'm in margin expansion, you'll have it significantly more revenue with the with the double business and you know you know a a strong global footprint in terms of being able to get more leverage with suppliers.
Is that a 235 year something lever that you might be able to pull in terms of of getting more leverage in your in your P. You know not just necessarily to make sure if the blood, but you know also being able to use a bigger size to your advantage.
Oh, absolutely and that was one of the one of the key underpinnings of my my thinking about expanding into Europe.
With the acquisition of skill and Suzanne and the others.
And and it's it's it's benefits to North America suppliers as well, if they're able to earn our business of Europe.
And needless more of a consolidated global price and volume partner.
So rationalizing those products and these different countries mm mm mm picking fewer suppliers, obviously means some suppliers loose and some suppliers pick up business I'll go with the otherwise gotten M and we think we get rewarded for.
For margin in price with that increased volume. So so yeah I think that's all that's exactly right.
Okay, Uhm I have more questions, but I don't want to get in front of your an investor day cause I I really want to talk about products that I'll I'll just hold off for two weeks.
Okay, perfect. We will see you see the investor that thank you.
Our next question comes from Andrew Cooper of Raymond James.
Yeah. Thanks for the questions, maybe starting with with Europeans go you said kind of at the high end of your expectations for the quarter as we try to think about the trajectory. There you know I know, there's some products that likely at some point you get called in and some moving parts there in the transition.
And the subscription so just.
Any flavor you can give on on each of those dynamics to help us think about that kind of where you are positioning was and thank you and what it might look like from there.
Yeah, So what we're doing those things and they're in process. So I don't see big kind of cool.
<unk> mountain climbing events in either direction cause they won't all happen at the same time, but as we were doing subscription recognition.
Certain areas now I'm trying to go to to that.
<unk>. So that we'll have this accident have <unk> 120, 14, and 15 just in terms of.
Dampened upfront revenue uhm, but better margin profile and so we're doing those things you know the way I look at it as as we we got on the field largely at the very beginning of the second quarter somewhere in the second third quarter.
Yeah, and when marginally into the fourth quarter about halfway through.
So we're putting that based on your own place.
And also the first quarter.
2021 will be the first fully or ownership for us and so we're sending that baseline.
And and the expectations, especially given the current situation.
Rowling Lockdowns and and those exist, though so we had a wonderful corner lived and we've done wonderfully even with those dynamics in place, but but there now rolling lockdowns them in Milan M. Lombardi for instance.
So.
So we can keep those things in mind. So she was our first year will include all of that noise. I guess is what I would say, Andrew but but for right. Now we're just we're sending that baseline year and and it's coming in nicely. Despite kind of the the dangers that work out there. So that's kind of how I look at it.
Okay. That's helpful and then maybe just one on.
On margins you know I think.
The the North American number whether impressive obviously in and it's kind of a new way for us to think about it but you know that the gross margin was with a knife number from our perspective and you know when I think about other players not necessarily in the animal house, but in general we've heard call out for you know shipping cough and and things like that being <unk>.
But it is there anything to note in the margin other than you know.
Hey, there's some shifts around around to mix it in the corner, but any off the sort of point out for us to think about I know you mentioned O V. P. I think had a strong.
Strong mixed component there so would love some advice.
Yeah, I think that's all he came mix I think it's it's consumables next witches, which is keen on gross margins.
And I think all my back to the 20th 13 14 plan you know you will call and say, Hey, we gotta get a product right.
What part of that product right and then you guys get margin right and you'd like that.
People right and then you have to get the model right. So the subscription fast type of model and then you scale it.
So yeah, I've never been a huge believer in stealing things that aren't.
Uhm profitable so I I think we just had a really positive peak at what we hope will be the future where the higher margin businesses that we emphasize so we put our shoulder behind represent a higher percentage of our business and our growth and and then a positive margin result.
From that and I think that's gross margin and eventually that closed down.
Through your adjusted operating margin. So I don't think it's anything more than what it looks like would look good next time, we had good top line growth of one sentence and have good margin.
Okay, Great and then maybe I wouldn't mind.
Oh, sorry go ahead.
Yeah, I would just add though that I I don't think we're coming off what we talked about an infection for the call for your basic.
Just to kind of clarify that on the on the consolidated for your gross margin.
Okay.
Great and then maybe just one last thing on them and I. Appreciate if you say, let's defer but just as we think about the quarter and some of the traction and the insurance that you've already at least brought to market whether it's the the D. Five acts or the R. C and kind of how to think about any trajectory. There any traction that you saw in the corner or what what adoption is look.
That'd be great.
I would just say they they both been good and when I would defer to investor diagnosed in terms of more that's in the pipeline.
But customer's always liked to adopt new box. That's that's that's the name of the game. So both of those are are now shipping and they're being received well and and the sales force also enthusiasm is is really important in new products for herself force.
It was a shot in the arm as well so in terms of analyzer, that's a little bit of a down onto the launching sometimes when they can't quite get into the clinics as aggressively as I'd like to but the adoption has been very good.
Alright, I appreciate it thanks for your time.
Thanks Center.
Our next question comes from Steven MA of paper Sandler.
Hi, guys. Thanks for taking the question that congrats on a on a great quarter.
<unk>.
Thank you.
Yes, <unk> covers a lot of ground already but it may be digging a little bit more accurate question and then you mentioned you're setting a baseline for this deal integration and you know I understand.
Have over for things, but you know <unk> could you maybe give us a little bit more color.
Sort of early.
Exactly for moving sales in here.
Model.
And when we should expect to see an effect on your on gross margins.
You know it's.
It's more of a multi your question I do think we will cover it an investor day, just in terms of of how much time, we move.
Uhm gross margins over the next three years and and what the stair steps look like so I think I will defer only 13 days and so it shouldn't take one number out of context, I think it'll be better for me.
Present kind of in the future in context in the next 13 days.
Okay, No that's fair enough money I appreciate that.
Alright, So my next question.
Yeah, really nice 323, and in any popping up and came back on again.
<unk>.
You too thanks.
<unk> and thoroughly washed through or do you think your savings and forget your best in the end.
Living here.
Well, that's a great question. So so I'm kind of two ways I I think two two is maybe a little low.
And we we called out some supply chain transitions that we were making.
So I think it was going to get a little bit low and we call him about because they have the benefit of being true and.
So we can resolve those issues. So we have a full performance in two three without the drag of a point or two just backlog on backlog, so our our own supply chain crate and and then I I suspect there there was a help or a couple of points.
The 15 point to to just put it in the context.
I suspect it was around around two percentage points.
And I think I think it's largely flushed through.
So I don't really expect that pop to continue.
Really is a kind of a catch up tailwind.
But to put it in the context of size I think it's probably a couple of points not that's not five or 10, when we don't see a supply chain brand like we saw on the second floor return them in the fourth quarter. So we feel pretty good about underlying demand that's real on it's not really a snap back with the exception of maybe maybe a cup.
<unk> that didn't come in to to the payment to three.
Okay, great. Thanks, Thanks for the color and maybe just sent my last question more sort of on a macro.
You know, let me see that you know the global demand for a companion animal health care has been you know very resilient.
Yeah, but you know it could you compare and contrast, or maybe where you see a major region in North America, and Europe, especially in light of you very soon.
European walk down maybe we can get that sent a new trend you're sitting right now.
My friends like 214.
Yeah, and these are just more amusing I think.
At this point, so so North America.
I think is fairly straightforward and we don't anticipate Lockdowns uhm.
Uhm.
Equivalent to what we had earlier in the year, but having said that in veterinary medicine pretty much worldwide and the market's elaborate is considered unnecessary.
Products, so even in Lombardi in Milan right now, they're gonna have walk down you can take your animals because that maryanne.
And and I also find sometimes on lockdown areas not the people are looking for excuses to get out of the house, but they you know they have the time and with the animal need some other veterinarian, even just for awhile that they would rather do it now while they.
Well they don't have the ability to do other things so I.
I I do think there will be rolling challenges Madrid, there's another hot spot.
<unk> periodically and I don't think we're out of the woods on that you don't need my commentary on.
It's gonna happen to Covid, I'm, not an epidemiologist, but I, but I do anticipate countries rolling.
Mm lockdowns partial or otherwise, but I think we've seen the movie.
And when I assume that letter of health care is necessary service that holds up really pretty well and I called about some of those schemes people who are at home with their Pepsi healthcare issues and then they have all the flexibility and the extra time, they're not running kids to sports, though not and I've gone to the pub or whatever it is.
To go pick put that extra time, the flexibility in their schedule that working from home.
For people to watch the kids all of those things.
And then the model.
<unk> with veterinarians are doing curbside check in but also do in general ashamed, a curbside check out that that leaves really pretty well towards the point of care test because once the pets in the back of the house. So I get to do the full work up would you do everything they get to recommend everything I'm gonna get to set baseline diagnostics.
All those things before they go back out to the curb and that tends to be pretty well too point of care testing as opposed to can you send in and out and having to wait a day or two so.
I'm fairly optimistic the.
Underlying demand for point of care diagnostics, those holding up fairly low and all the market's or lump or anything.
Okay, great Yeah, the that does some great additional color I appreciate it. Thank you so much.
Thank you.
The next question comes from Ben Hainer of L. I M Global partners.
Good then you guys can you hear me all right.
Good morning, then.
So just a couple of quicker ones for me just on the international Imogene <unk> the bigger than we had anticipated is that a fairly typical for what feel on the European firms might see in a in a Q3 and then is there any seasonality.
City, we should be cognizant of for the European businesses, where you go into the the last quarter of the year.
And then so I think it was probably a little bit better than we thought.
I think I'm. Some regard we're all flying in a little bit in the fog, but I think that was probably a little bit better than we thought with the with the dynamics with clinics.
That's a nice positive.
And I don't know now you're now you're just gonna get my opinion again, I I I think F 150 trucks had a big spike in Q3 as well so.
Yeah, I think I think people maybe have some pent up demand in terms of capital.
Equipment, maybe there are certain incentives in certain European countries that are that are helpful to that in terms of the best in your business.
But yeah. It was it was a it was a nice number and it's just too early we've only on the business for a couple of quarters now I'll just say that that's a that's a firm baseline we really would rather step back after 444 quarters of on her show up and say, Okay. What is.
What is it under our ownership compared to historical but that that was a positive number wasn't crazy, but it was it was definitely above my personal expectations.
Okay that makes sense cause I've got a F.
F 150 sales figures to the model now [laughter] from the you mentioned <unk> B I work from home <unk>, you know kind of the logistics <unk> flexibility that that families and pet owners have no <unk>, obviously work from home.
You know I guess in your sense of how big of a driver has that flexibility to the you know increased that visit to increase the <unk> you know ultimately increase diagnostic diagnostic usage.
So again, it's just personal commentary, but I have been in the business since the early nineties I think it's huge yeah. We've we've always said the single greatest lemon or to everybody's business and in the veterinary space is getting a pet to the hospital.
I'm getting your cat in your car and driving up to the veterinarian is is <unk>.
The challenge when people tend to keep you have very high compliance I trust the veterinarian a great deal and they should.
So getting them there is the barrier and and I think it's real and I think it's last I think the change is probably bigger.
Franklin in North America.
Where.
Blair flexible work at home type of arrangements and midday schedules are are less.
Cultural than they are saying, Spain. So I think it's probably a bigger ship for North America, but I personally think that the last thing one I think it'll be in play for quite a while.
Okay, I guess that makes sense now that everyone has the new F 152 so.
That's right. Thanks, a lot guys.
Thank you Ben.
As a reminder, ladies and gentlemen, <unk> wanted to ask the question.
The next question comes from Jim Pseudo T of Cydonia getting company.
Good morning can we can you hear me.
We can Jim how are you.
Well, well I still driving old Subaru, but other than that well two two quick questions.
If you will get you what you've done so far this year the guidance of the year you already indicated a a downturn.
<unk> revenue from the third quarter to four quarter, which historically for clues usually Mister <unk>.
Conservative and rug not update your guidance at this point.
Or was there something pulled into Q3 that you know think will be in Q4.
Well I don't I don't think it's a poll for question as much as.
Yes, it's so scary place out there and so when we look at it we we really have done it very thoughtful.
John about challenging the numbers on what to do with that when we think before your guide and you have to arrange in the full for your Guy those is probably Ah Ah correct place to be on a given given uncertainty. So I think we're gonna, we're gonna stick with that but there there's no.
There's nothing really I can give you that's a large movement and say hey, you know $10 million and this showed up in the third quarter I'm expected to them before I think it's really.
We started the ear with a full your guide and I think we're probably trying to the upper end of that but whatever we don't really want to move that up at this stage, especially given the fact that most of.
Most of the space is just refusing to say anything so we're we're trying to.
I'm trying to communicate especially can so I think we'll leave it where it's at.
Okay. So I really Miss environment, There's no reason to get a grant for you being a little conservative not not a term will too it'll take.
And then the other thing cancelled what what's going on with the tax rate why the the big charge you a quarter and how should we think about that go forward.
Yeah. So then we we just effectively reduce the carrying value of very preferred which is primarily related to be net operating loss.
That was driven by some very strategic tax and business strategies.
That has been coming cute fruition. So if you think about it going forward, we're really only.
You use the word camera only really caring about 7 million gross.
It's not does not have a valuation allowance applying to it so the the the volatility going forward, it's pretty minimized in that regard.
So I can go on and on a <unk>.
Are you going to report that you pay going forward or are you going to report.
I'm going to report a pulley tax number pay a smaller number anymore.
Is that alright, so we're going to it's it's it yeah. So what we'll do going forward unable certainly provide for your 2021 expected tax rate as part of the multiyear.
Well.
Okay, but but I am guessing that tax rate is gonna come down and 21 and 22 from.
What you thought it was gonna be at the beginning of this year.
Yep.
Okay alright, thank you.
You're welcome.
Is there are no further questions at this point I would like to tell them to call back to Mister Wilson Friday at the smaller closing remarks.
Hey, Thank you.
Thanks, everybody for joining the call I think it's pretty clear that task has accomplished a great deal.
This year.
The results for the quarter I think are wonderful I'm as pleased or or maybe even more excited about going for work inside of our business.
When I <unk> I'm on a pretty good place as we that's one of the second half of our five year plan. So I'm Super excited stay tuned we're working hard we expect to.
To continue to execute from the second half of our strategic plan and I will update you with Catherine of the team further 13 days from now that are Investor day, which is November 18th So I hope to virtually sue everybody there.
We're gonna, it's gonna be a <unk>, a great day Fender Bender, perhaps Scott.
Yeah, I hope to see it or so until M be safe.
The lessons and don't forget to take your pet to the veterinarian as we discussed let me know you have work at home time. So so take your pet to the vet alright, thanks, everybody have a good day.
<unk>.
Ladies and gentlemen that concludes today's conference call. Thank you for your participation tomato disconnect.
[music].